MedPath

Two Different Cataract Surgical Procedures to Prevent Posterior Capsule Opacification

Not Applicable
Conditions
Cataract
Posterior Capsule Opacification
Registration Number
NCT02445274
Lead Sponsor
Sun Yat-sen University
Brief Summary

In this study, the investigators introduce a new "capsule-reserved" cataract surgical procedure in which anterior lens capsule is reserved and attached onto posterior lens capsule in the purpose of preventing posterior capsule opacification (PCO). A prospective randomized controlled study is reported to compare the new "capsule-reserved" surgical procedure with conventional one on the effectiveness to prevent posterior capsule opacification in age-related cataract patients.

Detailed Description

A prospective, randomized controlled study of 240 eligible patients will been enrolled. Two eyes of each patient were assigned randomly to two groups respectively: Group I; anterior lens capsule is conventionally not reserved after continuous curvilinear capsulorhexis, while in Group II, anterior lens capsule is innovatively reserved and attached onto posterior lens capsule. This novel adjusted surgical procedure, featured by using the reserved anterior lens capsule to protect the peri-capsule microenvironment and prevent PCO, is conceptual different from the traditional cataract surgical procedure. Clinical examinations including posterior capsule opacification grading score, central posterior capsule thickness, central posterior capsule density, best corrected visual acuity, contrast sensitivity were carried out preoperatively and at each postoperative visit.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
240
Inclusion Criteria
  1. Aged 50 years or above
  2. Both eyes were diagnosed with age-related cataract
  3. Both eyes were planed to undergo the "Phacoemulsification and IOL implantation" surgery with 1 month
  4. Biocular BCVA improvement post surgery was feasible judged by the ophthalmologists.
Exclusion Criteria
  1. Other ocular diseases
  2. ACD<3CT
  3. Combined cataract surgery (trabeculoplasty, keratoplasty)
  4. Lens pseudoexfoliation syndrome combined with glaucoma or zonular abnormalities
  5. Previous intraocular surgery or trauma (laser not included)
  6. Uveitis
  7. Recent ocular infection
  8. Proliferative diabetic retinopathy
  9. Diabetes mellitus
  10. Congenital ocular abnormalities (aniridia, congenital cataract)
  11. Atrophy of iris
  12. Participants with previous clinical trials 30 days before surgery
  13. Using prostanoid eye drops
  14. Uncontrolled systematic diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from Baseline in posterior capsule opacification grading scorepost-operative day 1, post-operative week 1, post-operative month 1, post-operative month 3,

Posterior capsule opacification(PCO)was recorded by standardized slit lamp retroillumination images and analyzed using the EPCO2000 program. The severity of PCO was clinically graded from 0 (none) to 4 (severe)

Secondary Outcome Measures
NameTimeMethod
Change from Baseline in central posterior capsule thicknesspost-operative day 1, post-operative week 1, post-operative month 1, post-operative month 3, post-operative month 6, post-operative year 1

Central posterior capsule thickness was recorded and calculated by Pentacam HR system

Change from Baseline in central posterior capsule densitypost-operative day 1, post-operative week 1, post-operative month 1, post-operative month 3, post-operative month 6, post-operative year 1

Central posterior capsule density was recorded and calculated by Pentacam HR system.

Trial Locations

Locations (1)

Zhognshan Ophthalmic Center, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Zhognshan Ophthalmic Center, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Haotian Lin, M.D., Ph.D.
Contact
8613802793086
haot.lin@hotmail.com
Jing Li, M.D.
Contact
+86-20-87330341
Reviewborad_SYsU@163.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.